The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Supply and clinical application of Actinium-225 and Bismuth-213.
Open accessAbstract
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Worldwide, only three sources of 229Th are available (81).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationTargeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 418
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361
Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N. D., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S. M., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 272
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215
Self-citationCordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Müller‐Brand, J., Mäcke, H. R., Reubi, J. C., & Merlo, A. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1385-5 · Cited by 208
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229229 · Cited by 196
Research works printed but not linked: 3
- Kratochwil, 2015, Ac-225-DOTATOC - dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors, Eur J Nucl Med Mol Imaging, 42, S36
- Czerwinski K.Production of 225Ac from 229Th. Report on joint IAEA-JRC workshop “Supply of Actinium-225”. IAEA, Vienna, 2018. http://www-naweb.iaea.org/napc/iachem/working_materials.html
- Koning, 2013, Tendl-2012, NRG, Petten
Cited by
Sorted by citations
Items 101–141 of 141
The Emerging Potential of Lead-212 Theranostics
Plichta, K. A., & Buatti, J. M. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.11.001 · Cited by 3
Yamamoto, S., Yoshino, M., Shirasaki, K., Nakanishi, K., Kamada, K., Yoshikawa, A. L., & Kataoka, J. (2025) · Journal of Instrumentation · doi:10.1088/1748-0221/20/03/t03001 · Cited by 2
“The clinical efficacy of Ac-225 has been demonstrated in prostate-specific membrane antigen (PSMA) therapies [8], and these positive results have accelerated its clinical adoption [9].”
InfluentialChelator Design and Radiolabeling Chemistry of Radiometals
Krol, V. E., & Pandey, M. K. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00111 · Cited by 2
Liubchenko, G., Böning, G., Rumiantcev, M., Zounek, A. J., Zacherl, M. J., Sheikh, G. T., Resch, S., Werner, R. A., Ziegler, S. I., & Delker, A. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00800-0 · Cited by 2
“Despite the growing demand for 225 Ac in targeted alpha therapy (TAT), SPECT imaging of 225 Ac remains in its early stages of development [18, 19].”
Clinical perspective on targeted alpha therapy using 225Ac
Lim, I. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02117-5 · Cited by 2
“Efforts to produce 225 Ac using electron beams are also underway in several institutions [52], but these methods have not yet been commercialized.”
State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II
Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500128 · Cited by 2
Liang, Y., Xie, X., Zhou, Q., Zhao, S., Li, X., Chenchen, Y. U. A. N., HUANG, Z., Jun, T. U., & Li, X. (2025) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2025.100583 · Cited by 2
NANODIAMONDS AND CARBON NANOTUBES AS PERSPECTIVE CARRIERS OF BISMUTH ISOTOPES FOR NUCLEAR MEDICINE
Kazakov, A. G., Garashchenko, B. L., Babenya, J. S., Ivanova, M. K., Vinokurov, S. E., & Myasoedov, B. F. (2020) · RAD Conference Proceedings. · doi:10.21175/radproc.2020.01 · Cited by 2
Yamamoto, S., Yoshino, M., Shirasaki, K., Nakanishi, K., Kamada, K., Yoshikawa, A., & Kataoka, J. (2025) · Journal of Instrumentation · doi:10.1088/1748-0221/20/03/t03005 · Cited by 1
“The clinical efficacy of Ac-225 in prostate-specific membrane antigen (PSMA) therapies has been reported [8], and the positive impact of these results has accelerated its clinical use [9].”
Systematic study of thin barium/radium target production using electroplating method
Jajčišinová, E., Kellerbauer, A., Burdeinyi, D. D., Carrapiço, C., & Malmbeck, R. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112082 · Cited by 1
Medical radionuclide production in nuclear reactors – Sensitivity analysis to nuclear data
Ule-Duque, G., Capponi, L., & Margulis, M. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112391 · Cited by 1
Naka, S., Tadashi, W., Shirakami, Y., Ooe, K., Kurimoto, K., Sakai, T., Toyoshima, A., Murakami, M., Kon, Y., Haba, H., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00416-w · Cited by 2
Waste to resource: a review of critical raw materials recovery from spent nuclear fuel
Stamatin, S. N., Bonani, W., Blagoeva, D., & Cologna, M. (2026) · Sustainable Energy Technologies and Assessments · doi:10.1016/j.seta.2026.104926 · Cited by 1
Production of actinium-225 from a (n,p) reaction: Feasibility and pre-design studies
Abolaban, F. A., Banoqitah, E. M., Taha, E. M., Alhawsawi, A. M., Djouider, F., & Nisbet, A. (2021) · Nukleonika · doi:10.2478/nuka-2021-0008 · Cited by 1
“The accelerator method that uses Ra-226 has been investigated theoretically and experimentally and shows promising results [12, 15, 19].”
BackgroundMethodMorgan, K. A., & Donnelly, P. S. (2021) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2021.05.002 · Cited by 1
Vondrák, A., Bakova, S., Procka, V., Pinter, T., Lukáč, O., Haug, A. R., Sivoňová, M. K., Jurečeková, J., Poláček, H., Evin, D., et al. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00136-2 · Cited by 1
“The reason for their limited use, is the lack of production capacity, which is due to both the shortage of parent radionuclides and the number and productivity of production facilities [13–15].”
Sathekge, M. M., & Bouchelouche, K. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.014 · Cited by 1
Aktuelle radiopharmazeutische Entwicklungen für die theranostische Anwendung
Neels, O. C., Kratochwil, C., & Patt, M. (2021) · Radiopraxis · doi:10.1055/a-1525-6335
“Die Verfügbarkeit von Actinium-225 ist derzeit mangels Zulassung noch deutlich eingeschränkt [33, 34] und die Anwendung daher nur in Ausnahmefällen möglich.”
BackgroundMcDonagh, A. W., McNeil, B. L., Rousseau, J., Roberts, R., Merkens, H., Yang, H., Bénard, F., & Ramogida, C. F. (2022) · Research Square · doi:10.21203/rs.3.rs-1442932/v1
Production des radionucléides - Partie 2 : les accélérateurs de particules
Haddad, F. (2025) · Médecine Nucléaire · doi:10.1016/j.mednuc.2024.12.062
Sun, Y., Muxiao, W., Jijun, G., Qingchuan, L., Tu, J., & Xie, X. (2025) · Nuclear Analysis · doi:10.1016/j.nucana.2025.100157
Actinium purification from elemental components of stainless steel and aluminum
Klouda, J., Adelman, S. L., Aldrich, K. E., Kozimor, S. A., Lam, M. N., Lilley, L. M., Mocko, V., & Thiemann, S. L. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-024-09813-y
“Actinium-225 ( 225 Ac; t ½ = 9.92 d [1]) is a promising candidate for targeted alpha therapy [2] and is currently in Phase 1 – 3 clinical trials for treating various cancers.”
InfluentialAdvances with radiopharmaceutical therapy in cancer
Lepareur, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00002-9
Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II
Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2025.500128
Koniar, H., & Schaffer, P. C. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00056
Kaizuka, Y., Suzuki, H., Watabe, T., Ooe, K., Toyoshima, A., Takahashi, K., Sawada, K., Iimori, T., Masuda, Y., Uno, T., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26685606
McDonagh, A. W., McNeil, B. L., Rousseau, J., Roberts, R., Merkens, H., Yang, H., Bénard, F., & Ramogida, C. F. (2022) · Figshare · doi:10.6084/m9.figshare.20012962
Waste to resource: review of critical raw materials recovery from spent nuclear fuelPreprint
Stamatin, S. N., Bonani, W., Blagoeva, D., & Cologna, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5547077
Xu, L. L., Singh, S. K., Gaspar, N., Fan, J., Viglianti, B. L., & Zinn, K. R. (2026) · Molecules · doi:10.3390/molecules31061019
“For example, 211 At requires access to high-energy cyclotrons, and Bi-213 depends on the already constrained production of 225 Ac [159,160].”
Boschi, S., & Iorio, V. D. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100216
Monte Carlo modeling of targeted radionuclide therapy of micrometastases
Alcocer‐Ávila, M. (2021) · theses.fr (ABES) · doi:10.70675/d9d14d84z2d27z42c8z90e8zdd4b482de12f
Theranostics in Neuroendocrine Neoplasms
Adnan, A., & Basu, S. K. (2026) · PET Clinics · doi:10.1016/j.cpet.2026.03.002
Esnault, M., Gaschet, J., Touchefeu, Y., Ansquer, C., & Lugat, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102118
New measurements of the half-life of 225Ac at the NPL and IRA
Durán, M. T., Collins, S. M., Nedjadi, Y., Juget, F., Mohamud, H., Bhaisare, A., & Bailat, C. J. (2026) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2026.112741
Charge coupled device (CCD) camera for radiation imaging
Yamamoto, S. (2026) · Measurement Science and Technology · doi:10.1088/1361-6501/ae74ef
“Following encouraging clinical results, particularly in therapies targeting prostate-specific membrane antigen [23], clinical trials and intensive development of Ac-225 based radiopharmaceuticals are now underway [24, 25].”
Conceptual design of a mass separation system for high-purity actinium-225
Dong, Q., Li, Y., Jing, H., Wang, P., Tan, Z., Liu, J., Wang, Y., Dai, M., & Guo, Y. (2026) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2026.114190
Accelerating actinium-225 purification by high-pressure ion chromatography
Gaddis, K., Roach, B. D., Copping, R., Griswold, J. R., Mirzadeh, S., Stracener, D. W., Keever, T., & Davern, S. M. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467290
Chi, W. Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.19.745876
Quantitative SPECT imaging of 225 Ac and its daughters in mice in vivo
Du, S., Bobba, K. N., Peter, R., Gullberg, G. T., Flavell, R. R., Rodríguez, J. C., & Seo, Y. (2026) · Medical Physics · doi:10.1002/mp.70674
Kuang, X., Zhang, L., Tian, J., Zhang, R., Zhang, Y., & Luo, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01822
Determination of 226Ra in 225Ac Active Pharmaceutical Ingredients by ICP-QQQ-MS
Baumeister, J. E., Puffer, B. W., Toro-González, M., McCormick, J. B., Hawkins, C. A., & de Vries, D. J. (2026) · ACS Omega · doi:10.1021/acsomega.6c06224
Metadata
- Authors
- Morgenstern, A., Apostolidis, C., & Bruchertseifer, F.
- Affiliations
- European Commission (BE)
- Corresponding author
- Morgenstern, Alfred
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 50
- Issue
- 2
- Pages
- 119-123
- ISSN
- 0001-2998 (ISSN-L)
- PMC
- PMC7082773
- OpenAlex
- W3007334567
- Cited by
- 141
- References
- 45
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 23 · 2023: 19 · 2022: 15 · 2021: 29 · 2020: 8
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Seminars in Nuclear Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Funders
- Joint Research Centre
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
- Physical Sciences › Physics and Astronomy › Radiation › Radioactive Decay and Measurement Techniques
- Keywords
- actinium-225, bismuth-213, targeted alpha therapy, prostate cancer, radioisotope production, radionuclide supply, alpha-emitting radionuclides, neuroendocrine tumors, brain tumors, leukemia, bladder cancer
- MeSH terms
- Actinium, Bismuth, Humans, Isotope Labeling, Male, Prostatic Neoplasms, Radioisotopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
